Advanced mycosis fungoides: chemotherapy with etoposide, methotrexate, bleomycin, and prednimustine.
We assessed the efficacy and toxicity of a chemotherapeutic regimen in patients with stage II-IV mycosis fungoides. Eleven previously treated outpatients received etoposide and methotrexate p.o. and bleomycin i.v. every 3 weeks. There was 1 complete remission for 2 months and 7 partial remissions with a median duration of 6 months (range 2-16 months). Three patients showed stable disease lasting 1-5 months (median 2 months). In 4 patients, remissions were maintained with prednimustine after 10 courses of induction chemotherapy. Mild nausea occurred in all patients and severe leukocytopenia and thrombocytopenia in 1 patient. Toxicity of the treatment regimen was acceptable and response rates comparable to those seen by others with more toxic single-agent or combination chemotherapies.
Doberauer
C
C
Department of Internal Medicine, University of Essen, Federal Republic of Germany.
Ohl
S
S
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000188:drug therapy*; D011238:Prednimustine / Q000008:administration & dosage; D012878:Skin Neoplasms / Q000188:drug therapy*
D001761:Bleomycin; D005047:Etoposide; D011238:Prednimustine; D008727:Methotrexate